Rudruidee Karnchanasorn, MD
Endocrinology, Diabetes & Metabolism · Kansas City, KSNPI 1841313608
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,186 of the $1,511 with a category attached, or 78.5%. It is spread thinly across 17 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in KS, where the typical reported total is $1,553.
Across 32 payments — averaging $47.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$361
- Dexcom, Inc.$257
- Radius Health, Inc.$201
- BETA Bionics, Inc.$157
- Sanofi-aventis U.S. LLC$128
- Amgen$108
- plus $299 from 11 others
Across 4 payments — averaging $3312.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$13K
What the payments were for
- Speaking & faculty fees$32522%
- Food & beverage$1,18678%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 3 | $361 |
| Dexcom, Inc. | 7 | $257 |
| Radius Health, Inc. | 2 | $201 |
| BETA Bionics, Inc. | 1 | $157 |
| Sanofi-aventis U.S. LLC | 3 | $128 |
| Amgen | 2 | $108 |
| Abbott | 3 | $61 |
| Mannkind Corporation | 2 | $39 |
| Cequr Corporation | 1 | $34 |
| Lilly USA, LLC | 1 | $32 |
| Medtronic | 1 | $21 |
| Novartis | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $17 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,511 in reported general payments places this provider in the 45th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenotropinSomatropin | 22 | $98,390 |
| OzempicSemaglutide | 27 | $32,838 |
| JardianceEmpagliflozin | 22 | $27,772 |
| TrulicityDulaglutide | 13 | $17,848 |
| MounjaroTirzepatide | 15 | $15,460 |
| JanuviaSitagliptin Phosphate | 11 | $14,110 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $11,165 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $9,294 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $8,468 |
| Novolog FlexpenInsulin Aspart | 32 | $8,440 |
| Desmopressin AcetateDesmopressin (Nonrefrigerated) | 12 | $5,588 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $4,415 |
| NovologInsulin Aspart | 15 | $4,387 |
| Hydrocortisone | 56 | $4,069 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $16 | $37,22642 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $32 | $33,30728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Kansas City
- John MilesKansas City$13K
- Charlotte BurnsKansas City$3K
- Kristine GrdinovacKansas City$1K
- Aiman ZafarKansas City$492
- Tinni MishraKansas City$199
- Daniel TildenKansas City$128
- Prathyusha PagadalaKansas City$89
- Joseph KynerKansas City$74
- Leland GravesKansas City$57
- Abeer AnabtawiKansas City$56
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.